Kyverna Therapeutics Strengthens Leadership Team to Accelerate Next Phase of Growth

KYTX 12.13.2024

Full Press ReleaseSEC FilingsOur KYTX Tweets

About Gravity Analytica

Recent News

  • 01.21.2025 - Kyverna Therapeutics Appoints Naji Gehchan, MD, MBA, as Chief Medical and Development Officer
  • 01.14.2025 - Kyverna Therapeutics at J.P. Morgan Healthcare Conference
  • 01.13.2025 - Kyverna Therapeutics to Highlight Near-Term Strategic Priorities and Key Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.21.2025 - EX-99.1 EX-99.1
  • 01.21.2025 - 8-K Current report
  • 11.26.2024 - S-8 Securities to be offered to employees in employee benefit plans

Key Leadership Appointments Bring New Skills and Capabilities to Organization

EMERYVILLE, Calif.,Dec. 13, 2024/PRNewswire/ --Kyverna Therapeutics, Inc.(Kyverna), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced the recent appointments ofDan Maziaszas Chief Business Officer,Cara Baueras Chief Human Resources Officer, andTracy Rossinas Senior Vice President of Corporate Affairs, Communications and Investor Relations.

Image Credit: Kyverna Therapeutics (PRNewsfoto/Kyverna Therapeutics)

"I'm pleased to welcome three industry leaders to our Kyverna team," saidWarner Biddle, Chief Executive Officer of Kyverna. "Dan, Cara and Tracy bring important new skills and capabilities to Kyverna as we continue to support the company's next phase of growth and work to bring a transformative change to patients living with severe autoimmune diseases."

Mr. Maziaszbrings over 25 years of leadership and business experience across several leading biotechnology and large pharmaceutical companies.Mr. Maziaszmost recently served as Chief Business Officer at Atara Biotherapeutics, the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. At Atara,Mr. Maziaszled various corporate initiatives including strategic planning, licensing transactions with industry partners, and research collaborations with academic groups. Before his time at Atara,Mr. Maziaszwas Vice President, Corporate Strategy and Business Development at Kite Pharma, a global cell therapy leader, prior to its acquisition by Gilead Sciences. Mr. Maziasz also spent more than a decade at Amgen, where he held roles of increasing responsibility in the US,Europe, andAsiaacross business development, corporate strategy, finance, and commercial functions.

Ms. Bauerbrings more than 25 years of experience in global human resources leadership to Kyverna, having served most recently as Global Head of Human Resources at Kite, aGilead Company, where she oversaw all HR strategy and operations during a period of hypergrowth and global expansion which strengthened the company's leadership position in cell therapy. Prior to this role, she served as the Global Head of HR for the Entertainment Division at Riot Games where she worked directly with the founders to build anEntertainment Studioseparate from the core gaming business.Ms. Bauerhas also held various HR leadership roles at companies such as Netflix, Amgen, Gartner andNovo Nordisk.

Ms. Rossinbrings more than 20 years of strategic communications experience to Kyverna, having most recently served as the Head of Public Affairs at Kite, where she was responsible for leading corporate, product and employee communications in addition to patient advocacy. Prior to this role, she served as Vice President, Global Head of Communications at Innate Pharma, an oncology-focused biotech company, where she led both corporate and financial communications.Ms. Rossinalso spent more than 12 years at AstraZeneca/MedImmune, where she held multipleU.S.and global communications roles for key therapeutic areas across AstraZeneca's portfolio before serving as the Head of Corporate Affairs at MedImmune, the global biologics research and development arm of AstraZeneca. Before joining AstraZeneca, she held various positions at global public relations agencies working with corporate and healthcare related clients.

Inducement GrantIn connection with the appointment ofMr. Maziaszas Kyverna's Chief Business Officer, onDecember 9, 2024, Kyverna grantedMr. Maziaszan option to purchase 350,000 shares of its common stock (Option). The Option was granted pursuant to theKyverna Therapeutics, Inc.2024 Inducement Equity Incentive Plan, as approved by the Compensation Committee of Kyverna's Board of Directors onSeptember 14, 2024, and was granted as an inducement material toMr. Maziasz'semployment with Kyverna in accordance with Nasdaq Listing Rule 5635(c)(4). The exercise price of the Option was$4.86, the closing price of Kyverna's common stock onDecember 9, 2024, the date of grant. The Option will vest over four years, with 25% of the total number of shares subject to the Option vesting on the one-year anniversary ofMr. Maziasz'sappointment and 1/48th of the total number of shares subject to the Option vesting monthly thereafter, subject in each case toMr. Maziasz'scontinued service to Kyverna on each vesting date. Kyverna is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

AboutKyverna TherapeuticsKyverna Therapeutics, Inc.(Nasdaq: KYTX) is a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases. Our lead CAR T-cell therapy candidate, KYV-101 is advancing through clinical development with sponsored clinical trials across two broad areas of autoimmune disease: rheumatology and neurology, including Phase 2 trials for stiff-person syndrome, multiple sclerosis and myasthenia gravis, a Phase 1/2 trial for systemic sclerosis, and two ongoing multi-center Phase 1/2 trials inthe United StatesandGermanyfor patients with lupus nephritis. Kyverna's pipeline includes next-generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.

For more information, please visithttps://kyvernatx.com.

Forward-Looking StatementsStatements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." The words, without limitation, "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these or similar identifying words. Forward-looking statements in this press release include, without limitation, those related to: the potential impact of the clinical outcomes from the ongoing clinical programs; the potential impact of the new data on the treatment efficacy and safety profile of KYV-101; the potential that the results of the ongoing trials could drastically change the treatment landscape for the targeted autoimmune diseases; Kyverna's goals to develop certain paradigm-shifting treatment options; the potential for KYV-101 to provide durable, immunosuppressant-free remission for autoimmune disease patients; Kyverna's beliefs about the differentiated properties of KYV-101; and Kyverna's clinical trials, investigator-initiated trials and named-patient activities. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to market conditions, and other factors discussed in the "Risk Factors" section of Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that Kyverna has filed or may subsequently file with theU.S. Securities and Exchange Commission. Any forward-looking statements contained in this press release are based on the current expectations of Kyverna's management team and speak only as of the date hereof, and Kyverna specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Contact:Investors:InvestorRelations@kyvernatx.comMedia:media@kyvernatx.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/kyverna-therapeutics-strengthens-leadership-team-to-accelerate-next-phase-of-growth-302331659.html

SOURCEKyverna Therapeutics

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com